Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its […]
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy
REGENXBIO today announced that the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment […]
Modus Therapeutics Submits Patent Application for Sevuparin in Kidney Disease
Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet medical […]
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib
Takeda has today announced that it has entered into an exclusive licensing agreement with HUTCHMED […]
Ferronova Secures A$11 Million to Advance Nanotech Image-guided Cancer Therapy
Australian biotech company Ferronova has announced it has secured a further A$11 million to progress […]
Priothera Announces First Patients Enrolled in Pivotal Global Study for Patients with Acute Myeloid Leukemia
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound […]
US FDA Accepts Supplemental New Drug Application for Jardiance® for Adults with Chronic Kidney Disease
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) […]
Evaxion Receives FDA Fast-track Designation for Personalized Cancer Immunotherapy
Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today […]
Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood
Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing […]
Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Cutaneous Melanoma
Linnaeus Therapeutics, a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more